PCAC Meeting — July 23–24, 2026

The Pharmacy Compounding Advisory Committee will meet July 23–24, 2026 to recommend final 503A Bulks List placement for the twelve peptides reclassified by the FDA on April 15. This is the most consequential single regulatory decision in the peptide category in over a decade.

What the committee will decide

For each of the twelve peptides individually, PCAC will recommend one of three outcomes:

• Full approval — placed on the 503A Bulks List without restrictions.
• Approval with restrictions — placed on the list with conditions on indication, route, or prescriber credential.
• Referred for further study — decision deferred 6–18 months pending additional submissions.

A fourth outcome — return to Category 1 / outright prohibition — is considered unlikely absent new safety signals. PCAC recommendations are advisory; the FDA historically adopts them with high fidelity.

Our pre-meeting outlook (will be updated as the docket publishes)

Based on evidence base, prior PCAC voting patterns, and pre-meeting industry signals. Will be revised as the public docket publishes ~30 days before the meeting.

Public comment

The Federal Register docket for the July meeting will publish approximately 30 days in advance at regulations.gov. Any party may submit a written comment. Comments from clinicians and patients with direct experience carry the most procedural weight.

Live coverage plan

We will publish a live brief during each session day of the July 23–24 meeting, with same-day analysis and a full post-decision briefing within 72 hours of the close. Subscribers to the Daily Brief receive live coverage by email; this page will be updated continuously throughout the meeting.